AstraZeneca, still in asset-sale mode, hands off most global rights for constipation med Movantik

AstraZeneca's Movantik sale comes months after the drugmaker offloaded most commercial rights for heartburn med Losec. (AstraZeneca)

British drugmaker AstraZeneca has spent much of the past few years in asset-sale mode, offloading of a range of its specialty products in return for extra cash to plow into areas such as oncology. Now, AstraZeneca has agreed to divest the rights to one of its GI meds in a move the acquirer is calling a "transformative event" for its business. 

AstraZeneca has pawned off most of its global rights for GI med Movantik to Tel Aviv- and North Carolina-based RedHill Biopharma in a deal valued at $67.5 million, the drugmaker said Tuesday.

As part of the sublicense deal, which doesn't include rights in Europe, Canada or Israel, AstraZeneca will receive $52.5 million in cash upfront with an additional $15 million due in 2021. RedHill will acquire U.S. rights to the drug through a co-commercial deal AstraZeneca signed with Daiichi Sankyo in 2015. 


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.

AstraZeneca will continue to manufacture and supply Movantik during a "transition period" to RedHill, the company said. Movantik, an oral, once-daily treatment for opioid-induced constipation, posted $96 million in sales in 2019, AstraZeneca said. 

RELATED: AstraZeneca backs away from acid reflux with Losec rights sale—even with Zantac stumbling